NCT07190469View on ClinicalTrials.gov

PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

February 28, 2029

Conditions

Triple Negative Breast Cancer (TNBC)Advanced Solid Tumors Cancer

Interventions

DRUG

PQ203

PQ203 is a peptide drug-conjugate given once weekly by intravenous infusion intended for the treatment of advanced solid tumor cancers including triple negative breast cancer.

Trial Locations (1)

M5G 0C6

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

ProteinQure Inc.

INDUSTRY

NCT07190469 - PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter